Prospective observational study shows improved treatment adherence and quality of life in T2DM patients, suggesting pharmacist involvement is beneficial.
Clinical pharmacist‐led guidance was evaluated in a 6‑month prospective observational study of 90 T2DM patients at a tertiary care hospital. Participants were distributed into test (Group A; n = 45) and control (Group B; n = 45) groups. Group A received structured clinical pharmacist counselling on medication regimens, adherence, lifestyle modifications, and ADR monitoring, whereas Group B received standard care. Outcomes measured at baseline and 2 months included glycaemic profiles, lipid profile, medication adherence (MARS‑10), and quality of life (WHOQOL‑BREF). Group A exhibited significant improvements in FBS, PPBS, medication adherence, and quality of life physical and psychological domains. HbA1c and lipid profile showed favourable but non‑significant trends. No major ADRs were reported. These findings support integration of pharmacist‑led guidance and care in chronic disease management.
No takes yet. Share an insight, caveat, or question.
Dutta et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: